Sanctuary Advisors LLC Purchases 4,118 Shares of Icon Plc $ICLR

Sanctuary Advisors LLC boosted its position in shares of Icon Plc (NASDAQ:ICLR) by 83.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,050 shares of the medical research company’s stock after acquiring an additional 4,118 shares during the quarter. Sanctuary Advisors LLC’s holdings in Icon were worth $1,001,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ICLR. WINTON GROUP Ltd bought a new stake in Icon during the second quarter valued at approximately $254,000. Daiwa Securities Group Inc. boosted its holdings in Icon by 19.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after buying an additional 4,546 shares during the period. Frontier Capital Management Co. LLC increased its stake in Icon by 97.6% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock worth $10,379,000 after buying an additional 35,253 shares in the last quarter. Peapack Gladstone Financial Corp purchased a new stake in Icon in the 2nd quarter worth $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Icon by 58.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 289 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Stock Down 2.7%

Shares of ICLR opened at $165.76 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.14 and a quick ratio of 1.14. The stock has a market capitalization of $12.69 billion, a price-to-earnings ratio of 29.49, a price-to-earnings-growth ratio of 8.14 and a beta of 1.22. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The business’s 50 day simple moving average is $151.11 and its 200-day simple moving average is $136.43.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ICLR shares. Mizuho upped their price objective on Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a research note on Friday, June 26th. Barclays lifted their target price on Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research note on Thursday, June 25th. BMO Capital Markets upped their price target on Icon from $160.00 to $187.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. JPMorgan Chase & Co. increased their price objective on shares of Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. Finally, Citigroup lifted their price objective on shares of Icon from $140.00 to $165.00 and gave the company a “neutral” rating in a research report on Thursday, June 25th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Icon presently has a consensus rating of “Hold” and a consensus price target of $168.73.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.